Experts say that the Novavax Covid vaccine could prove to be more safe for children than current UK jabs. 

It is hoped that the US shot — which uses tried and true vaccine technology and is manufactured in Teeside — could reduce hesitancy and boost uptake in children. 

The UK Government already has 60million doses of Novavax on order and trials show it is 96 per cent effective in adults.

However, it has been shown to produce fewer side effect than the ones triggered by Moderna’s or Pfizer vaccines. 

If approved, this vaccine (known scientifically as NVXCoV2373) would be first to be approved in the UK.

Children are given protein-based jabs to prevent the flu, meningitis, and hepatitis. 

Novavax's injection, officially known as NVX-CoV2373, would be the first protein-based jab approved in the UK, if given the green light. Protein-based jabs are already given to children to protect against the flu, meningitis and hepatitis

Novavax’s injectable, also known as NVXCoV2373 in the UK would be the UK’s first approved protein-based jab if it is granted the go ahead. To protect children against the flu and meningitis, protein-based jabs have been given.

MailOnline has been told that experts believe approval of the vaccine will allow for it to be rolled out to children. They also encourage the people who have been hesitant about getting the shot to do so.  

Last month, the final data of the study were sent to the Medicines and Healthcare Products Regulatory Agency. The approval was expected within days.   

Another option for injections to combat Covid that have been approved in the UK is either a viral vector vaccine (AstraZeneca) or an mRNA vaccine (Pfizer, Moderna).

Novavax has proteins that mimic coronavirus spikes. This causes Novavax to trigger the production of antibodies in the body.

The body will be able to fight off coronavirus if it encounters it in the future.

Two doses of the injection are administered 21 days apart. Novavax is not like other jabs, which need to be kept at extreme temperatures. It can be kept in an ordinary fridge for as long as three months. 

The third phase, which Novavax in Maryland found to be more than 15,000 UK residents, was also discovered by Novavax The jab was effective against moderate, severe and mild coronavirus-related diseases at 96.4 percent. 

In the meantime, the US and Mexico tested the vaccine against 30,000 patients and found that it provided 100 percent protection against severe and moderate disease.  

Protein vaccines already in use include the hepatitis B and meningitis jabs, which are routinely given to newborns.

The UK has saved thousands of lives by using vaccines, and hChiefs of the ealth said that children’s rollout will keep them in schools.

In July, more than 1million children in England were made to miss school because of the virus.

Only one-tenth of over-18s in England have yet to receive their first dose before November 18.

The uptake was only 38.4 percent among 12- to 15-years-olds, and 63.9 % of 16- to 17-years-olds had received a first dose. 

The small risk the virus poses to children, as well as concerns about myocarditis after vaccination, are thought to be factors behind the low uptake.

Data from the Joint Committee on Vaccination and Immunisation shows up to one in 56,000 12 to 15-year-olds will get myocarditis after their first Covid jab.

However, the rate increases to one in every 23,000 patients after two doses.

AstraZeneca has also been associated with blood clots in young people. This prompted health authorities to limit AstraZeneca injections to over-40-year-olds.

Novavax data from trials shows that Novavax only caused mild side effects with no significant adverse effects.

Its study did not include under-18s and was not big enough to pick up on either of the very rare side effects, but found that adults overall tolerated the jab well, with reported side effects being mild and short-lived. 

Novavax currently tests its vaccine on 2200 12- to 17-year olds in the US.

Similar results were also seen with other Covid vaccines, however experts feel confident that Novavax will be successful if it is made available to the public. 

MailOnline was told by Professor Neil Mabbott of the University of Edinburgh that Novavax has less side effects than current injections in the UK. This means Novavax could be an alternative for children who are at low risk of experiencing potentially serious side effects.

He said that similar technology using protein-based technology was used in routine childhood vaccinations for many years. 

Professor Mabbott explained that the vaccine may offer some security reassurance for those who were hesitant to receive their Covid vaccination. 

“This could also reduce concerns that parents might have regarding the administration of vaccines to their children. It could also have an impact on the uptake of vaccines.

“It’s important to note that severe side effects such as blood clots or heart inflammation after vaccination with the mRNA (Pfizer, Moderna), and adenovirus (AstraZeneca and Janssen) covid vaccines are very uncommon.